Literature DB >> 28077583

A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.

Kristen K Pierce1, Stephen S Whitehead2, Beth D Kirkpatrick1, Palmtama L Grier3, Adrienne Jarvis1, Heather Kenney2, Marya P Carmolli1, Cynthia Reynolds1, Cecilia M Tibery3, Janece Lovchik3, Anna Janiak3, Catherine J Luke2, Anna P Durbin3, Alexander G Pletnev2.   

Abstract

West Nile virus (WNV) is a major cause of mosquito-borne illness in the United States. Human disease ranges from mild febrile illness to severe fatal neurologic infection. Adults aged >60 years are more susceptible to neuroinvasive disease accompanied by a high mortality rate or long-lasting neurologic sequelae. A chimeric live attenuated West Nile virus vaccine, rWN/DEN4Δ30, was shown to be safe and immunogenic in healthy adults aged 18-50 years. This study evaluated rWN/DEN4Δ30 in flavivirus-naive adults aged 50-65 years and found it to be safe and immunogenic. Outbreaks of WNV infection tend to be unpredictable, and a safe and effective vaccine will be an important public health tool.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  West Nile virus; flavivirus; vaccine

Mesh：

Substances：

Year:  2016        PMID： 28077583      PMCID： PMC5225253          DOI： 10.1093/infdis/jiw501

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  13 in total

1.  Phylogenetic analysis of North American West Nile virus isolates, 2001-2004: evidence for the emergence of a dominant genotype.

Authors:  C Todd Davis; Gregory D Ebel; Robert S Lanciotti; Aaron C Brault; Hilda Guzman; Marina Siirin; Amy Lambert; Ray E Parsons; David W C Beasley; Robert J Novak; Darwin Elizondo-Quiroga; Emily N Green; David S Young; Lillian M Stark; Michael A Drebot; Harvey Artsob; Robert B Tesh; Laura D Kramer; Alan D T Barrett
Journal:  Virology       Date:  2005-08-31       Impact factor: 3.616

2.  Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors.

Authors:  Kathryn A Hanley; Laura B Goddard; Lara E Gilmore; Thomas W Scott; James Speicher; Brian R Murphy; Alexander G Pletnev
Journal:  Vector Borne Zoonotic Dis       Date:  2005       Impact factor: 2.133

3.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

Authors:  A P Durbin; R A Karron; W Sun; D W Vaughn; M J Reynolds; J R Perreault; B Thumar; R Men; C J Lai; W R Elkins; R M Chanock; B R Murphy; S S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

4.  West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy.

Authors:  Alexander G Pletnev; Robert Putnak; Jim Speicher; Eric J Wagar; David W Vaughn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

5.  Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.

Authors:  Alexander G Pletnev; David E Swayne; Jim Speicher; Alexander A Rumyantsev; Brian R Murphy
Journal:  Vaccine       Date:  2006-06-21       Impact factor: 3.641

Review 6.  West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States.

Authors:  Edward B Hayes; Duane J Gubler
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

7.  West Nile virus neuroinvasive disease incidence in the United States, 2002-2006.

Authors:  Nicole P Lindsey; Stephanie Kuhn; Grant L Campbell; Edward B Hayes
Journal:  Vector Borne Zoonotic Dis       Date:  2008       Impact factor: 2.133

8.  Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.

Authors:  Olga A Maximova; James M Speicher; Jeff R Skinner; Brian R Murphy; Marisa C St Claire; Danny R Ragland; Richard L Herbert; Dan R Pare; Rashida M Moore; Alexander G Pletnev
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

9.  Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010.

Authors:  L R Petersen; P J Carson; B J Biggerstaff; B Custer; S M Borchardt; M P Busch
Journal:  Epidemiol Infect       Date:  2012-05-28       Impact factor: 4.434

10.  Evolution of new genotype of West Nile virus in North America.

Authors:  Allison R McMullen; Fiona J May; Li Li; Hilda Guzman; Rudy Bueno; James A Dennett; Robert B Tesh; Alan D T Barrett
Journal:  Emerg Infect Dis       Date:  2011-05       Impact factor: 6.883
View more
  9 in total

Review 1.  Newer Vaccines against Mosquito-borne Diseases.

Authors:  Anju Aggarwal; Neha Garg
Journal:  Indian J Pediatr       Date:  2017-05-31       Impact factor: 1.967

Review 2.  A 20-year historical review of West Nile virus since its initial emergence in North America: Has West Nile virus become a neglected tropical disease?

Authors:  Shannon E Ronca; Jeanne C Ruff; Kristy O Murray
Journal:  PLoS Negl Trop Dis       Date:  2021-05-06

3.  Role of NS1 and TLR3 in Pathogenesis and Immunity of WNV.

Authors:  Sameera Patel; Alessandro Sinigaglia; Luisa Barzon; Matteo Fassan; Florian Sparber; Salome LeibundGut-Landmann; Mathias Ackermann
Journal:  Viruses       Date:  2019-07-03       Impact factor: 5.048

Review 4.  West Nile virus vaccines - current situation and future directions.

Authors:  Sebastian Ulbert
Journal:  Hum Vaccin Immunother       Date:  2019-07-10       Impact factor: 3.452

5.  Pathogenicity and virulence of West Nile virus revisited eight decades after its first isolation.

Authors:  Juan-Carlos Saiz; Miguel A Martín-Acebes; Ana B Blázquez; Estela Escribano-Romero; Teresa Poderoso; Nereida Jiménez de Oya
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

6.  Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.

Authors:  Patricia Kaaijk; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2017-11-29       Impact factor: 3.452

7.  Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine.

Authors:  Maryann Giel-Moloney; Ana P Goncalvez; John Catalan; Valerie Lecouturier; Yves Girerd-Chambaz; Fernando Diaz; Francisco Maldonado-Arocho; Raul C Gomila; Marie-Clotilde Bernard; Ray Oomen; Simon Delagrave; Nicolas Burdin; Harold Kleanthous; Nicolas Jackson; Jon Heinrichs; Konstantin V Pugachev
Journal:  Sci Rep       Date:  2018-09-04       Impact factor: 4.379

Review 8.  Twenty Years of Progress Toward West Nile Virus Vaccine Development.

Authors:  Jaclyn A Kaiser; Alan D T Barrett
Journal:  Viruses       Date:  2019-09-05       Impact factor: 5.048

9.  Characteristics of Chimeric West Nile Virus Based on the Japanese Encephalitis Virus SA14-14-2 Backbone.

Authors:  Guohua Li; Xianyong Meng; Zhiguang Ren; Entao Li; Feihu Yan; Jing Liu; Ying Zhang; Zhanding Cui; Yuetao Li; Hongli Jin; Zengguo Cao; Le Yi; Pei Huang; Hang Chi; Hualei Wang; Weiyang Sun; Tiecheng Wang; Yuwei Gao; Yongkun Zhao; Songtao Yang; Xianzhu Xia
Journal:  Viruses       Date:  2021-06-29       Impact factor: 5.048
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.